Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Edward J Wild"'
Autor:
Florian Lipsmeier, Cedric Simillion, Atieh Bamdadian, Rosanna Tortelli, Lauren M Byrne, Yan-Ping Zhang, Detlef Wolf, Anne V Smith, Christian Czech, Christian Gossens, Patrick Weydt, Scott A Schobel, Filipe B Rodrigues, Edward J Wild, Michael Lindemann
Publikováno v:
Journal of Medical Internet Research, Vol 24, Iss 6, p e32997 (2022)
BackgroundRemote monitoring of Huntington disease (HD) signs and symptoms using digital technologies may enhance early clinical diagnosis and tracking of disease progression, guide treatment decisions, and monitor response to disease-modifying agents
Externí odkaz:
https://doaj.org/article/be7ef03add614a4cbbff46610a18dd00
Autor:
Alexander J Lowe, Simon Sjödin, Filipe B Rodrigues, Lauren M Byrne, Kaj Blennow, Rosanna Tortelli, Henrik Zetterberg, Edward J Wild
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0233820 (2020)
Molecular markers derived from cerebrospinal fluid (CSF) represent an accessible means of exploring the pathobiology of Huntington's disease (HD) in vivo. The endo-lysosomal/autophagy system is dysfunctional in HD, potentially contributing to disease
Externí odkaz:
https://doaj.org/article/abadd71913544f01ab9800c20c4666ba
Autor:
Nicholas S. Caron, Lauren M. Byrne, Fanny L. Lemarié, Jeffrey N. Bone, Amirah E.-E. Aly, Seunghyun Ko, Christine Anderson, Lorenzo L. Casal, Austin M. Hill, David J. Hawellek, Peter McColgan, Edward J. Wild, Blair R. Leavitt, Michael R. Hayden
Publikováno v:
Translational Neurodegeneration, Vol 13, Iss 1, Pp 1-22 (2024)
Abstract Background Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated in clinical trials. Sensiti
Externí odkaz:
https://doaj.org/article/89b2e043ae1a4ef094cfbb9512ed2741
Autor:
Davina J Hensman Moss, Nicola Robertson, Ruth Farmer, Rachael I Scahill, Salman Haider, Michela A Tessari, Geraldine Flynn, David F Fischer, Edward J Wild, Douglas Macdonald, Sarah J Tabrizi
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0189891 (2017)
BackgroundHuntington's disease (HD) is an autosomal dominant neurodegenerative condition caused by an expanded CAG repeat in the gene encoding huntingtin (HTT). Optimizing peripheral quantification of huntingtin throughout the course of HD is valuabl
Externí odkaz:
https://doaj.org/article/69dc0fa445cd4ae2b1e1251644f48668
Autor:
Filipe Brogueira Rodrigues, Lauren M Byrne, Peter McColgan, Nicola Robertson, Sarah J Tabrizi, Henrik Zetterberg, Edward J Wild
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0163479 (2016)
IntroductionImmune system activation is involved in Huntington's disease (HD) pathogenesis and biomarkers for this process could be relevant to study the disease and characterise the therapeutic response to specific interventions. We aimed to study i
Externí odkaz:
https://doaj.org/article/7ba145aa92a64787927cbeeb71315450
Autor:
Chiara Zuccato, Manuela Marullo, Barbara Vitali, Alessia Tarditi, Caterina Mariotti, Marta Valenza, Nayana Lahiri, Edward J Wild, Jenny Sassone, Andrea Ciammola, Anne Catherine Bachoud-Lèvi, Sarah J Tabrizi, Stefano Di Donato, Elena Cattaneo
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e22966 (2011)
Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a number of patho-physiological conditions, most notably, in Huntington's disease (HD), a progressive neurodegenerative disorder. Since BDNF is also produced in blood, we
Externí odkaz:
https://doaj.org/article/6756c12baf744436bc09cc501fc27853
Publikováno v:
Journal of Huntington's Disease. 11:351-367
In this edition of the Huntington’s Disease Clinical Trials Corner, we expand on the PIVOT HD (PTC518), and SIGNAL (pepinemab) trials, and list all currently registered and ongoing clinical trials in Huntington’s disease. We also introduce a ‘b
Publikováno v:
Journal of Huntington's Disease. 11:105-118
In this edition of the Huntington’s Disease Clinical Trials Corner we expand on GENERATION HD1, PRECISION-HD1 and PRECISION-HD2, SELECT-HD, and VIBRANT-HD trials, and list all currently registered and ongoing clinical trials in Huntington’s disea
Autor:
Filipe B, Rodrigues, Gail, Owen, Swati, Sathe, Elena, Pak, Dipinder, Kaur, Anka G, Ehrhardt, Sherry, Lifer, Jenny, Townhill, Katarzyna, Schubert, Blair R, Leavitt, Mark, Guttman, Jee, Bang, Jan, Lewerenz, Jamie, Levey, Cristina, Sampaio, Edward J, Wild
Publikováno v:
Journal of Huntington's Disease. 11:59-69
Background: Biomarkers are needed to monitor disease progression, target engagement and efficacy in Huntington’s disease (HD). Cerebrospinal fluid (CSF) is an ideal medium to research such biomarkers due to its proximity to the brain. Objective: To
Autor:
Annett Boeddrich, Christian Haenig, Nancy Neuendorf, Eric Blanc, Andranik Ivanov, Marieluise Kirchner, Philipp Schleumann, Irem Bayraktaroğlu, Matthias Richter, Christine Mirjam Molenda, Anje Sporbert, Martina Zenkner, Sigrid Schnoegl, Christin Suenkel, Luisa-Sophie Schneider, Agnieszka Rybak-Wolf, Bianca Kochnowsky, Lauren M. Byrne, Edward J. Wild, Jørgen E. Nielsen, Gunnar Dittmar, Oliver Peters, Dieter Beule, Erich E. Wanker
BackgroundAlzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) peptides in intra- and extracellular deposits. How Aβ aggregates perturb the proteome in brains of patients and AD transgenic mouse models, however, remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3169de1db8693df74f26650a22b528ff
https://doi.org/10.1101/2023.01.16.523715
https://doi.org/10.1101/2023.01.16.523715